Condition: Mild Alzheimer's Disease · Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease · Sponsor: Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
This description comes directly from the study's public registry record.
CMS CAG · 410-786-2281 · CMS_caginquiries@cms.hhs.gov
Always discuss trial participation with your own doctor first.
| Centers for Medicare and Medicaid Services | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06058234